口服埃博拉病毒样颗粒疫苗在小鼠中诱导特异性体液与细胞免疫
本研究开发了含埃博拉病毒GP、NP和VP40的病毒样颗粒(VLP)口服疫苗,在雌性C57BL/6小鼠中比较口服与肌内注射三剂免疫效果。结果显示口服免疫可诱导抗GP和NP的IgG、中和抗体及NP特异性CD8+ T细胞,且应答略优于肌内注射,为口服VLP疫苗提供概念验证。
要点
- 口服VLP疫苗可诱导抗EBOV-GP和NP的IgG及中和抗体。
- 口服免疫可产生EBOV-NP特异性CD8+ T细胞应答。
- 口服组免疫应答略优于肌内注射组,但保护效力等仍需验证。
核心结论
- 口服VLP候选疫苗可在小鼠中诱导抗原特异性体液和细胞免疫,提供概念验证。
研究设计与样本
- 用转染HEK-293T细胞产生含EBOV GP、NP和VP40的VLP,经超速离心浓缩并电镜表征。
- 雌性C57BL/6小鼠共14只,肌内注射组4只(30 μg/剂)、口服组8只(300 μg/剂),间隔两周共三剂,对照组2只未免疫。
主要发现
- 口服免疫诱导针对EBOV-GP和EBOV-NP的抗原特异性IgG应答。
- 中和试验证实血清抗体可抑制EBOV-GP假型病毒(rVSV)感染。
- 流式细胞术显示接种小鼠产生EBOV-NP特异性CD8+ T细胞。
- 口服组免疫应答较肌内注射组略有改善。
临床怎么用
- 目前仅为小鼠概念验证,尚不能用于临床或公共卫生接种建议。
局限性
- 保护效力、免疫持久性、安全性、最佳剂量方案及跨相关动物模型的可转化性均需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ebola virus (EBOV) poses a significant public health threat due to its high case fatality rates and proved human-to-human transmission. While licensed vaccines exist for EBOV, their intramuscular administration presents some logistical challenges in outbreak settings. Oral vaccines offer advantages in accessibility, compliance, and scalability but have not been explored for EBOV. METHODS: We developed an orally-administered EBOV vaccine using virus-like particles (VLPs) incorporating the EBOV glycoprotein (GP), nucleoprotein (NP), and viral protein 40 (VP40). VLPs were produced via transfection of HEK-293T cells, concentrated through ultracentrifugation, and characterized by electron microscopy. Female C57BL/6 mice (n = 14) were immunized intramuscularly (30 μg/dose, n = 4) or orally (300 μg/dose, n = 8) with three doses at two-week intervals. Control mice (n = 2) received no immunization. Immune responses were evaluated by ELISA for anti-EBOV- GP, and anti-EBOV-NP antibodies, neutralization assays using recombinant vesicular stomatitis pseudovirus (rVSV-pseudotyped with EBOV-GP), and flow cytometry for the characterization of EBOV-NP-specific CD8+ T cells. RESULTS: Oral immunization with EBOV FPLs induced antigen-specific IgG responses against EBOV-GP and EBOV-NP. Neutralization assays confirmed the presence of serum antibodies capable of inhibiting EBOV-GP pseudotyped virus infection, while flow cytometry analysis revealed development of EBOV-NP-specific CD8+ T cells in vaccinated mice. Notably, immune responses in orally vaccinated animals were slightly improved compared to those elicited by intramuscular administration. CONCLUSION: This study provides a proof-of-concept that an oral VLP-based EBOV vaccine candidate can induce antigen-specific humoral and cellular immune responses in mice. However, additional studies are required to determine protective efficacy, durability of immunity, safety, optimal dosing regimens, and translatability across relevant animal models before clinical development can be considered.
引用
- Lasala F, Luczkowiak J, Labiod N, et al. Oral immunization with virus-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice. Vaccine. 2026. PMID: 42217450. doi:10.1016/j.vaccine.2026.128764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。